PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Currently, chronic obstructive pulmonary disease (COPD) is a 5-largest cause of death worldwide, and the reduced activities of daily living, productivity and disability explain a significant economic and social damage. World Health Organization (WHO) predicts, that COPD will be a 3-largest cause of...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2015-03-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/37 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849696692458225664 |
|---|---|
| author | A. U. Kulikov I. A. Komarov |
| author_facet | A. U. Kulikov I. A. Komarov |
| author_sort | A. U. Kulikov |
| collection | DOAJ |
| description | Currently, chronic obstructive pulmonary disease (COPD) is a 5-largest cause of death worldwide, and the reduced activities of daily living, productivity and disability explain a significant economic and social damage. World Health Organization (WHO) predicts, that COPD will be a 3-largest cause of death worldwide. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We performed budget impact analysis on the basis of two bronchodilators in Russian Federation – tiotropium bromide (Spiriva) and ipratropium bromide (Atrovent) in COPD treatment. Changing treatment option from Atrovent to Spiriva provides economic benefit and permit to treat additionallyCOPD patients for the same period. |
| format | Article |
| id | doaj-art-ef20d094e97840ca9efbeded2bde1148 |
| institution | DOAJ |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2015-03-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-ef20d094e97840ca9efbeded2bde11482025-08-20T03:19:23ZrusIRBIS LLCФармакоэкономика2070-49092070-49332015-03-0153202631PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASEA. U. Kulikov0I. A. Komarov1Laboratory of pharmacoeconomic researches of the First Moscow State Medical University named after I.M. Sechenov, MoscowLaboratory of pharmacoeconomic researches of the First Moscow State Medical University named after I.M. Sechenov, MoscowCurrently, chronic obstructive pulmonary disease (COPD) is a 5-largest cause of death worldwide, and the reduced activities of daily living, productivity and disability explain a significant economic and social damage. World Health Organization (WHO) predicts, that COPD will be a 3-largest cause of death worldwide. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We performed budget impact analysis on the basis of two bronchodilators in Russian Federation – tiotropium bromide (Spiriva) and ipratropium bromide (Atrovent) in COPD treatment. Changing treatment option from Atrovent to Spiriva provides economic benefit and permit to treat additionallyCOPD patients for the same period.https://www.pharmacoeconomics.ru/jour/article/view/37pharmacoeconomic analysischronic obstructive pulmonary diseasetiotropium bromidespiriva ipratropium bromideatrovent, budget impact analysis |
| spellingShingle | A. U. Kulikov I. A. Komarov PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Фармакоэкономика pharmacoeconomic analysis chronic obstructive pulmonary disease tiotropium bromide spiriva ipratropium bromide atrovent, budget impact analysis |
| title | PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| title_full | PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| title_fullStr | PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| title_full_unstemmed | PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| title_short | PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| title_sort | pharmacoeconomic study over use of anticholinergic bronchodilators spiriva and atrovent for treatment of chronic obstructive pulmonary disease |
| topic | pharmacoeconomic analysis chronic obstructive pulmonary disease tiotropium bromide spiriva ipratropium bromide atrovent, budget impact analysis |
| url | https://www.pharmacoeconomics.ru/jour/article/view/37 |
| work_keys_str_mv | AT aukulikov pharmacoeconomicstudyoveruseofanticholinergicbronchodilatorsspirivaandatroventfortreatmentofchronicobstructivepulmonarydisease AT iakomarov pharmacoeconomicstudyoveruseofanticholinergicbronchodilatorsspirivaandatroventfortreatmentofchronicobstructivepulmonarydisease |